Showing 1 - 4 of 4 Amyotrophic Lateral Sclerosis (ALS)
A Phase I Trial to Evaluate Safety and Tolerability of Abatacept followed by Subcutaneous Interleukin-2 Administration in Patients with Amyotrophic Lateral Sclerosis

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Aramide Balogun

Phone: 713.441.6947

In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combina ... Read more >

A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Aramide Balogun

Phone: 713.441.6947

The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >

COMPILATIONS OF CLINICAL FINDINGS IN AMYOTROPHIC LATERAL SCLEROSIS

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: KaDeesia Brown

Phone: 713.441.9120

The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Met ... Read more >

Genomic Translation for ALS Clinical Care

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progre ... Read more >